Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, South Korea.
Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Aliment Pharmacol Ther. 2022 Oct;56(7):1146-1156. doi: 10.1111/apt.17161. Epub 2022 Jul 23.
The optimal treatment goal in Crohn's disease (CD) is endoscopic healing (EH). However, transmural healing (TH) facilitated by the development and increasing performance of magnetic resonance enterography (MRE) is emerging as a potential treatment goal.
To assess TH rates after 1 year of treatment by MRE and its relationship with EH in paediatric patients with CD receiving anti-tumour necrosis factor (TNF) agents, and to investigate factors associated with TH after 1 year of treatment.
This multi-centre, prospective, observational study included Korean paediatric patients with luminal CD diagnosed at age < 19 years who were naïve to anti-TNF treatment. They simultaneously underwent ileocolonoscopy and MRE at baseline and after 1 year of treatment with biologics.
We included 116 patients. At 1 year, EH and TH were achieved in 59.5% (69/116) and 38.8% (45/116) of the patients, respectively. Both EH and TH was observed in 35.3% (41/116), EH without TH in 24.1% (28/116), TH without EH in 3.4% (4/116), and neither EH nor TH in 37.1% (43/116). Moreover, 59.4% (41/69) of patients who achieved EH at 1 year exhibited TH, and 91.1% (41/45) of patients who achieved TH exhibited EH. Baseline MaRIA score was associated with TH according to a multivariate analysis (OR 0.97, 95% CI 0.95-0.99, p = 0.023).
TH is a more stringent goal than EH. Regular follow-up evaluation of transmural status, and efforts to achieve TH, may alter the natural course of CD in the era of treat-to-target.
在克罗恩病(CD)中,最佳的治疗目标是内镜下愈合(EH)。然而,磁共振肠成像(MRE)的发展和性能的提高使得黏膜下愈合(TH)成为一个潜在的治疗目标。
评估接受抗肿瘤坏死因子(TNF)治疗的儿童 CD 患者在 MRE 治疗 1 年后 TH 的发生率及其与 EH 的关系,并研究治疗 1 年后 TH 的相关因素。
这是一项多中心、前瞻性、观察性研究,纳入了年龄<19 岁且未经 TNF 治疗的韩国腔型 CD 患儿。他们在基线和接受生物制剂治疗 1 年后同时进行了回结肠镜检查和 MRE。
共纳入 116 例患者。1 年后,EH 和 TH 的达成率分别为 59.5%(69/116)和 38.8%(45/116)。EH 和 TH 均达到的比例为 35.3%(41/116),EH 但未达到 TH 的比例为 24.1%(28/116),TH 但未达到 EH 的比例为 3.4%(4/116),EH 和 TH 均未达到的比例为 37.1%(43/116)。此外,在 1 年内达到 EH 的患者中有 59.4%(41/69)达到了 TH,在达到 TH 的患者中有 91.1%(41/45)达到了 EH。多变量分析显示,基线 MaRIA 评分与 TH 相关(OR 0.97,95%CI 0.95-0.99,p=0.023)。
TH 比 EH 是一个更严格的目标。在靶向治疗时代,定期对黏膜下状态进行随访评估,并努力实现 TH,可能会改变 CD 的自然病程。